ClinicalTrials.gg
CompletedNCT01946568Updated Jun 23, 2015

A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.

A Phase 1 interventional study of Dalbavancin in Bacterial Infections., sponsored by Durata Therapeutics Inc., an affiliate of Allergan plc. Completed at 12 sites in 2 countries. Open to participants aged 3 Months to 11 Years. Per ClinicalTrials.gov, last updated 2015-06-23.

Sponsored by Durata Therapeutics Inc., an affiliate of Allergan plc (part of AbbVie) · Phase 1 and Interventional

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
3 Months to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 181 studies in Bacterial Infections with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Bacterial Infections · United States.

Planned enrollment
109th of 151
36 · median 62
Started
2013
with 11 others
Phase 1
66 of 181
2 open now
Registered
69th of 181
by date

Among the 181 studies in Bacterial Infections with a site in United States, this one is the 109th largest by planned enrollment of the 151 interventional ones that give a count, is one of 12 that started in 2013, is one of 66 in phase 1, and was the 69th registered.

Bacterial Infections

586 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

12 of the 181 studies in Bacterial Infections with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 56 Bacterial Infections studies recruiting now, 38 (68%) set no upper age limit and 13 (23%) stop at 75 or younger; 18 take children under 18; 6 take healthy volunteers.

This study: 3 Months to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 181 studies in Bacterial Infections with a site in United States, or all of them as a file.
02

Study summary

A phase one study to characterize the pharmacokinetics of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive) following the intravenous administration of a single dose of dalbavancin.

Read the detailed description

This is a open label, multi center study to investigate the pharmacokinetics, safety and tolerability of a single dose of intravenous dalbavancin in hospitalized pediatric patients with known or suspected bacterial infection. Patients will be enrolled and results will be evaluated in 3 age cohorts as follows:

Cohort 1: Patients 6 years to 11 years of age, inclusive; Cohort 2: Patients 2 years to \<6 years of age; Cohort 3: Patients 3 months to \<2 years of age.

All patients in each cohort will be administered a single dose of dalbavancin in addition to background anti infective treatment to be chosen by the investigator according to standard of care. Pharmacokinetic samples will be obtained at various timepoints. Dalbavancin can be administered at any time (before, during or after) the standard of care therapy.

03

Conditions studied

  • Bacterial Infections.

Browse trials for

04

Who can participate

Ages eligible
3 Months to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized patients who will be receiving at least 24 hours of appropriate non- intravenous anti-infective treatment for known or suspected bacterial infections with the exception of urinary tract infections.
  • Written parental .
  • Able to comply with the protocol for the duration of the study.
  • Expected to survive throughout the study.
  • Normal audiologic assessment within 3 days prior to the study drug infusion.

Exclusion criteria

Exclusion Criteria:

  • drug within 30 days or 5 half-lives, whichever is longest, preceding the first dose of study medication.
  • History of fluctuant hearing, persistent tinnitus, balance disorder, otologic surgery or disease, tumor of the head, neck, or auditory system, head injury, Meniere's disease, inner ear disease, perilymphatic fistula, CNS disorder resulting in hearing deficits, or significant noise exposure.
  • Significant exposure to aminoglycoside antibiotics or chemotherapy currently or within a week prior to enrollment into the study or current use of loop diuretics.
  • Patients continuing on vancomycin treatment or are anticipated to begin vancomycin or other glycopeptide treatment during the 7 day period after dalbavancin administration.
  • Patients with any abnormality other than that associated with their underlying disease. Aminotransferases (, ALT) >5 x ; total and alkaline phosphatase) >2 x ULN.
  • Albumin \< half lower limit of normal or physical exam evidence of malnutrition.
  • Patients who are less than one year of age, and were born with gestational age of less than 32 weeks.
  • Positive urine (or serum) pregnancy test at screening (post menarchal females only) or after admission (prior to dosing).
  • Known to have to glycopeptides.
  • Calculated \<30 ml/min using the Schwartz method.
  • Pregnant or nursing females.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Single dose Dalbavancin

    Drug: Dalbavancin

Interventions

  • Intravenous dalbavancin given at 15 mg/kg (not to exceed 1000 mg) for patients ≥5 years of age, and 25 mg/kg for patients \<5 years of age.

06

What researchers measure

Primary outcomes

  1. To characterize the pharmacokinetics in pediatric patients by measuring AUC 0-inf of dalbavancin.

    To characterize the pharmacokinetics of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive) following the intravenous administration of a single dose of dalbavancin.

    Time frame: At 0.5 hours, 4 hours, 12 hours, 24 hours,144 hours and 648 hours post-dose.

  2. To characterize the pharmacokinetics in pediatric patients by measuring Cmax of dalbavancin.

    To characterize the pharmacokinetics of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive) following the intravenous administration of a single dose of dalbavancin.

    Time frame: At 0.5 hours, 4 hours, 12 hours, 24 hours,144 hours and 648 hours post-dose.

  3. To characterize the pharmacokinetics in pediatric patients by measuring AUC0-last of dalbavancin.

    To characterize the pharmacokinetics of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive) following the intravenous administration of a single dose of dalbavancin.

    Time frame: At 0.5 hours, 4 hours, 12 hours, 24 hours,144 hours and 648 hours post-dose.

  4. To characterize the pharmacokinetics in pediatric patients by measuring AUC0-t of dalbavancin.

    To characterize the pharmacokinetics of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive) following the intravenous administration of a single dose of dalbavancin.

    Time frame: At 0.5 hours, 4 hours, 12 hours, 24 hours,144 hours and 648 hours post-dose.

  5. To characterize the pharmacokinetics in pediatric patients by measuring Tmax of dalbavancin.

    To characterize the pharmacokinetics of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive) following the intravenous administration of a single dose of dalbavancin.

    Time frame: At 0.5 hours, 4 hours, 12 hours, 24 hours,144 hours and 648 hours post-dose.

  6. To characterize the pharmacokinetics in pediatric patients by measuring t1/2 of dalbavancin.

    To characterize the pharmacokinetics of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive) following the intravenous administration of a single dose of dalbavancin.

    Time frame: At 0.5 hours, 4 hours, 12 hours, 24 hours,144 hours and 648 hours post-dose.

Secondary outcomes

  1. To evaluate the safety of a single dose of dalbavancin which will be measured by adverse event monitoring.

    Time frame: one year

  2. To evaluate the safety of a single dose of dalbavancin which will be measured by clinical laboratories (hematology and serum chemistry).

    Time frame: one year

  3. To evaluate the safety of a single dose of dalbavancin which will be measured by blood pressure and pulse rate.

    Time frame: one year

07

Study locations

12 sites
  • University Arkansas Medical Center
    Little Rock, Arkansas 72202, United States
  • University of California, San Diego
    San Diego, California 92123, United States
  • Connecicut Children's Hospital
    Hartford, Connecticut 06106, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • University of Michigan Medical Center
    Ann Arbor, Michigan 48109, United States
  • Columbia University
    New York, New York 10032, United States
  • Duke Medical Center
    Durham, North Carolina 27710, United States
  • Pediatric Pharmacology
    Toledo, Ohio 43606, United States
  • Texas Children's Hospital - Clinical Care Center
    Houston, Texas 77030, United States
  • Tallin's Children Hospital Pediatric Clinic
    Tallinn, 13419, Estonia
  • Tartu University Hospital Anesthesiology & Intensive Care
    Tartu, 51015, Estonia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2013
First posted
Sep 19, 2013
Start
Jun 2013
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Last update
Jun 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01946568
Responsible party
Sponsor
First posted
Sep 19, 2013
Start date
Jun 2013
Primary completion
Apr 2015
Completion
Apr 2015
Last update
Jun 23, 2015

Study contacts

Michael Dunne, MD
study director · Durata Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dalbavancin

Start the discussion